A BILL 
To require the Secretary of Health and Human Services 
to maintain a list of the country of origin of all drugs 
marketed in the United States, to ban the use of Federal 
funds for the purchase of drugs manufactured in the 
People’s Republic of China, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Protecting our Phar-
4
maceutical Supply Chain from China Act of 2022’’. 
5
00:08 Mar 22, 2022
H7121
2 
•HR 7121 IH
SEC. 2. COUNTRY OF ORIGIN OF DRUGS. 
1
(a) IN GENERAL.—Subchapter A of chapter V of the 
2
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 
3
et seq.) is amended by adding at the end the following: 
4
‘‘SEC. 524B. REGISTRY OF DRUGS PRODUCED OUTSIDE THE 
5
UNITED STATES. 
6
‘‘(a) IN GENERAL.—The Secretary shall compile and 
7
maintain a list of all drugs approved under subsection (c) 
8
or (j) of section 505 of this Act or licensed under sub-
9
section (a) or (k) of section 351 of the Public Health Serv-
10
ice Act, and any active ingredients in such drugs, that— 
11
‘‘(1) are manufactured outside of the United 
12
States; and 
13
‘‘(2) are determined by the Secretary to be crit-
14
ical to the health and safety of consumers in the 
15
United States. 
16
‘‘(b) ADDITIONAL LIST.—In conjunction with the list 
17
described in subsection (a), the Secretary shall compile 
18
and maintain a list of drugs included on such list that 
19
are exclusively produced in, or use active or inactive ingre-
20
dients produced in, the People’s Republic of China. 
21
‘‘(c) REQUIREMENT.—The list described in sub-
22
section (a) shall, with respect to each drug included on 
23
the list, provide information about the supply chain of the 
24
drug, including each step in the supply chain that occurs 
25
prior to importation of the drug into the United States.’’. 
26
00:08 Mar 22, 2022
H7121
3 
•HR 7121 IH
(b) FEDERAL HEALTH PROGRAM PURCHASE
OF 
1
DRUGS.— 
2
(1) IN GENERAL.—Notwithstanding any other 
3
provision of law, the Department of Health and 
4
Human Services, the Department of Veterans Af-
5
fairs, the Department of Defense, and any other 
6
Federal health care program (as defined in section 
7
1128B(f) of the Social Security Act (42 U.S.C. 
8
1320a–7b(b))), with respect to the purchase of a 
9
drug by such agency or program, the following shall 
10
apply: 
11
(A) Beginning on January 1, 2023, such 
12
agency or program may purchase only drugs for 
13
which 60 percent or more of the active pharma-
14
ceutical ingredients are manufactured in coun-
15
tries described in paragraph (2). 
16
(B) Beginning on January 1, 2024, such 
17
agency or program may purchase only drugs for 
18
which 100 percent of the active pharmaceutical 
19
ingredients are manufactured in countries de-
20
scribed in paragraph (2). 
21
(2) COUNTRIES DESCRIBED.—The countries de-
22
scribed in this paragraph are countries— 
23
(A) other than the People’s Republic of 
24
China; and 
25
00:08 Mar 22, 2022
H7121
4 
•HR 7121 IH
(B) that meet the health and safety stand-
1
ards of the Food and Drug Administration. 
2
(3) WAIVERS.—The Secretary of Health and 
3
Human Services may issue waivers of the require-
4
ments under paragraph (1) for any agency or pro-
5
gram that is unable to meet such requirements and 
6
demonstrates a need for the waiver. No waiver may 
7
be issued under this paragraph for drugs that are 
8
purchased on or after January 1, 2026. 
9
(c) LABELING REQUIREMENT.—Section 502 of the 
10
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) 
11
is amended by adding at the end the following: 
12
‘‘(gg) If it is a drug and its labeling does not specify 
13
the country of origin of each active ingredient contained 
14
in the drug.’’. 
15
SEC. 3. TEMPORARY 100 PERCENT EXPENSING FOR PHAR-
16
MACEUTICAL AND MEDICAL DEVICE MANU-
17
FACTURING PROPERTY. 
18
(a) IN GENERAL.—For purposes of section 168(k) of 
19
the Internal Revenue Code of 1986, in the case of any 
20
qualified pharmaceutical and medical device manufac-
21
turing property which is placed in service after December 
22
31, 2019, and before January 1, 2027— 
23
(1) such property shall be treated as qualified 
24
property (within the meaning of such section), 
25
00:08 Mar 22, 2022
H7121
5 
•HR 7121 IH
(2) the applicable percentage otherwise deter-
1
mined under section 168(k)(6) of such Code with re-
2
spect to such property shall be 100 percent, and 
3
(3) paragraph (8) of such section shall not 
4
apply. 
5
(b) QUALIFIED PHARMACEUTICAL
AND MEDICAL 
6
DEVICE MANUFACTURING PROPERTY.—For purposes of 
7
this section, the term ‘‘qualified pharmaceutical and med-
8
ical device manufacturing property’’ means any tangible 
9
property placed in service in the United States as part 
10
of the construction or expansion of property for the manu-
11
facture of drugs (as defined in section 201(g) of the Fed-
12
eral Food, Drug, and Cosmetic Act (21 U.S.C. 321(g))) 
13
or medical devices (as defined in section 201(h) of such 
14
Act (21 U.S.C. 321(h))). 
15
Æ 
00:08 Mar 22, 2022
H7121
